• Highlighting a platform-centric gene editing strategy that harmonizes clinical protocols and manufacturing processes, allowing a single target modification to be applied across multiple autoimmune indications
• Showcasing a multi-indication clinical development pathway that leverages Phase I safety and mechanistic insights to accelerate Phase II expansion, streamlining translation across diverse disease contexts

NEW DATA